How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
The objective of this study was to determine if PROSTASCINT image quality can be significantly improved by applying resolution recovery techniques while simultaneously reducing image acquisition times. PROSTASCINT studies were obtained on twelve consecutive patients using a dual-head Philips SKYLight camera. Images were processed using filtered back projection (FBP), standard3D-OSEM, and with Philips' Astonish software. The Astonish software implements a matched filtering technique to control noise, even when iterating enough to recover image features that are not obvious with standardprocessing. The full, three quarter and half count image sets reconstructed with Astonish software were compared to the full count images processed with FBP and 3D-OSEM. In three patients who also had pelvic CT scans, the CT datasets were used to generate attenuation maps and attenuation correction (AC)and scatter correction (SC) were applied.
On subjective evaluation, Astonish processing significantly improves there solution and quality of PROSTASCINT SPECT images. CT attenuation andscatter correction provide further improvement. Astonish-processed images using half the total number of counts appeared superior to images processedwith FBP and images using 75% of the counts were superior to images processedwith 3D-OSEM. These findings suggest use of Astonish processing would make itpossible to significantly shorten acquisition times without compromising image quality.
"This data presented at the SNM meeting adds to the growing body of peerreviewed clinical literature and presentations at major medical meetings reporting the clinical utility and positive outcomes associated with advanced PROSTASCINT imaging," commented Michael D. Becker, president and chief executive officer of Cytogen.
About Prostate Cancer
Prostate cancer is the most common type of cancer found in American men, other than skin cancer. In 2006, the American Cancer Society estimates thatthere will be about 234,000 new cases of prostate cancer in the United States and that about 27,000 men will die from the disease. It is estimated thatthere are more than 2 million American men currently living with prostatecancer. Tests to determine the amount of prostate-specific antigen (PSA), aprotein produced by the cells of the prostate gland, in the blood along with adigital rectal exam is used to help initially detect prostate cancer and isalso used to monitor patients with a history of prostate cancer to see if thecancer has come back, or recurred. PSA levels cannot directly identify the extent or location of disease.
Cytogen's PROSTASCINT molecular imaging agent is the first and only commercial product targeting PSMA. PROSTASCINT consists of a monoclonal antibody (7E11.C5.3) directed against PSMA that is linked to the imagingradioisotope Indium-111. By targeting PSMA, the PROSTASCINT molecular imaging procedure can detect the extent and spread of prostate cancer using a standard gamma camera.